Clinical Trials Logo

Cancer clinical trials

View clinical trials related to Cancer.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT03739372 Not yet recruiting - Cancer Clinical Trials

Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma

PNOC008
Start date: November 1, 2018
Phase: N/A
Study type: Interventional

This is a 2 strata pilot trial within the Pacific Pediatric Neuro-Oncology Consortium (PNOC). The study will use a new treatment approach based on each patient's tumor gene expression, whole-exome sequencing (WES), whole-genome sequencing (WGS), targeted panel profile (UCSF 500 gene panel), quantitative proteomics, and RNA-Seq. The current study will test the efficacy of such an approach in children with High-grade gliomas HGG.

NCT ID: NCT03733990 Not yet recruiting - Cancer Clinical Trials

A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients

MATINS
Start date: December 1, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is a first in human study to identify whether FP-1305 is suitable to use in humans. The previous pre-clinical studies have demonstrated that FP-1305 binds to a receptor known as CLEVER-1. CLEVER-1 has been shown to support tumour growth. No significant adverse events were witnessed in primates and the dose used will be 300 fold lower than the dose provided to primates which showed no toxicity. The patients with advanced melanoma, ovarian, pancreatic, colorectal or liver cancer who have exhausted all licenced therapeutic options will die due to their disease. Based on the investigator's existing data CLEVER-1 is expressed in these tumour types. Inhibition of CLEVER-1 with FP-1305 may have an anti-tumour effect in these patients.

NCT ID: NCT03727698 Not yet recruiting - Cancer Clinical Trials

Prospective Evaluation of Radiotherapy Using Magnetic Resonance Image Guided Treatment

PERMIT
Start date: November 2018
Phase: N/A
Study type: Interventional

The purpose of PERMIT is to collect information on the treatment of radiotherapy patients using a new radiotherapy machine that includes magnetic Resonance (MR) imaging (MR linac) to guide treatment. The aim is to use this information to support the introduction of MR Linac into clinical practice. PERMIT will collect details on patients treated on the MR linac plus details on their side effects and other outcomes. This information plus technical and imaging information will be combined with information from other centres using this machine. By doing so this will help us learn how best to use the MR Linac in the future and design new radiotherapy protocols

NCT ID: NCT03717402 Not yet recruiting - Cancer Clinical Trials

Smartphone Technology to Alleviate Malignant Pain (STAMP)

Start date: January 1, 2019
Phase: N/A
Study type: Interventional

This research study is developing and evaluating a new pain management app for cancer patients (STAMP).

NCT ID: NCT03712566 Not yet recruiting - Cancer Clinical Trials

Multi-Omic Assessment of Squamous Cell Cancers Receiving Systemic Therapy

MASST
Start date: October 2018
Phase:
Study type: Observational

This is prospective research study which will include patients with recurrent or metastatic squamous cell carcinoma of the head and neck, esophagus and anal canal starting on first-line platinum based chemotherapy or any line of immunotherapy treatment.This study aims to characterize the dynamic changes in genomic, epigenetic, immune profiling and imaging data during treatment with systemic therapy. Patients will have archived tumor samples requested as well as blood samples collected at up to four time points to analyze these changes. Imaging data will be derived from patients' routine CT scans before and after treatment.

NCT ID: NCT03712436 Not yet recruiting - Cancer Clinical Trials

Examining Early Palliative Care in Newly Diagnosed Cancer Patients

Start date: November 30, 2018
Phase: N/A
Study type: Interventional

To understand the impact of initiation of palliative care in this low-resource setting, and whether palliative care is a cost-reducing intervention that will improve patient-reported outcomes and quality of life.

NCT ID: NCT03708224 Not yet recruiting - Cancer Clinical Trials

Phase II Study of Perioperative Immunotherapy in Patients With Advanced Non-Virally Associated Squamous Cell Carcinoma

Start date: November 1, 2018
Phase: Phase 2
Study type: Interventional

To determine the effect of neoadjuvant atezolizumab alone or in combination with emactuzumab, CPI-444, and other immune modulating agents on T-cell infiltration in advanced SCCHN. To determine the impact of neo-adjuvant immunotherapy on surgical outcomes.

NCT ID: NCT03707301 Not yet recruiting - Cancer Clinical Trials

Post-SOPHrology Cancer Patients' anxieTY Report

SOPHTY
Start date: October 20, 2018
Phase:
Study type: Observational

Cancer is pathology with a high impact on patients and relatives quality of life. Most of the time, it is a stressful trial. Professionals have often resort to pharmaceutical solutions, but sometimes, it is not sufficient. So, patients resort to alternative and complementary medicines, as sophrology. In Lucien Neuwirth Cancer Institute, patients can benefit from sophrology. Anxiety levels have never been reported before and after sessions. Indeed, the present study wants to report anxiety levels before, after, and one and three weeks after session. Levels of satisfaction will also be reported.

NCT ID: NCT03694431 Not yet recruiting - Cancer Clinical Trials

Comparative Trial of Home-Based Palliative Care

HomePal
Start date: January 2019
Phase: N/A
Study type: Interventional

Background: To effectively alleviate suffering and improve quality of life for patients with serious illness and their caregivers, palliative care (PC) services must be offered across multiple settings. Research is needed to determine how best to optimize home-based palliative care (HBPC) services to meet the needs of individuals with high symptom burden and functional limitations. Aim: The investigators will compare a standard HBPC model that includes routine home visits by a nurse and provider with a more efficient tech-supported HBPC model that promotes timely inter-professional team coordination via synchronous video consultation with the provider while the nurse is in the patient's home. The investigators hypothesize that tech-supported HBPC will be as effective as standard HBPC. Design: Cluster randomized trial. Registered nurses (n~130) will be randomly assigned to the tech-supported or standard HBPC model so that half of the patient-caregiver dyads will receive one of the two models. Setting/Participants: Kaiser Permanente (15 Southern California and Oregon sites). Patients (n=10,000) with any serious illness and a prognosis of 1-2 years and their caregivers (n=4,800) Methods: Patients and caregivers will receive standard PC services: comprehensive needs assessment and care planning, pain and symptom management, education/skills training, medication management, emotional/spiritual support; care coordination, referral to other services, and 24/7 phone assistance. Results: Primary patient outcomes: symptom improvement at 1 month and days spent at home in the last six months of life; caregiver outcome: perception of preparedness for caregiving. Conclusion: Should the more efficient tech-supported HBPC model achieves comparable improvements in outcomes that matter most to patients and caregivers, this would have a lasting impact on PC practice and policy.

NCT ID: NCT03690401 Not yet recruiting - Cancer Clinical Trials

Body Composition Post Cancer Treatment

PostSOZO
Start date: October 2018
Phase:
Study type: Observational

The purpose of this study is to assess how bone density and body composition changes after a cancer patient completes treatment and through 12-weeks post-treatment. Patients who enroll in the 12-week exercise program, Moving On, and those that do not elect to participate in the Moving On program will both be tracked, with assessments including SOZO measurements, DEXA scan (bone density and whole body composition), performance status tests, food log, urine color test, and other study assessments.